BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Niu Y, Ji H. Current developments in extracellular-regulated protein kinase (ERK1/2) inhibitors. Drug Discovery Today 2022. [DOI: 10.1016/j.drudis.2022.01.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Pang K, Wang W, Qin J, Shi Z, Hao L, Ma Y, Xu H, Wu Z, Pan D, Chen Z, Han C. Role of protein phosphorylation in cell signaling, disease, and the intervention therapy. MedComm 2022;3. [DOI: 10.1002/mco2.175] [Reference Citation Analysis]
2 Fu L, Chen S, He G, Chen Y, Liu B. Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: An Update on Pharmacological Small-Molecule Inhibitors. J Med Chem 2022. [PMID: 36205714 DOI: 10.1021/acs.jmedchem.2c01244] [Reference Citation Analysis]
3 Song Y, Bi Z, Liu Y, Qin F, Wei Y, Wei X. Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.05.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]